Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989-Reference-Cited by-同舟云学术

Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989

Published:2010-01 Issue:1 Volume:46 Page:160-169
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Schaapveld Michael,Visser Otto,Siesling Sabine,Schaar Cees G.,Zweegman Sonja,Vellenga Edo

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. Association of Comprehensive Cancer Centres [homepage on the Internet]. Utrecht: The Netherlands. http://www.ikcnet.nl/cijfers/index.php?taal=nl&frequentiemaat=1®io=Landelijk&soort_kanker=50&soort_morfologie=&periode=2005&inputRegioLandelijk=on&inputRegioMZ=&fInvasief=1&uitkomstmaat=2&periode_input=2005&leeftijdsklassen=1.

2. Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens;Alexanian;JAMA,1969

3. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma;Samson;Lancet,1989

4. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials;Gregory;J Clin Oncol,1992

5. A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma;Abrahamson;Br J Haematol,1996

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailty;Journal of Geriatric Oncology;2024-03

2. Risk of atrial fibrillation in patients with multiple myeloma: what is known and directions for future study;The Egyptian Heart Journal;2024-02-01

3. Multiple Myeloma in Young Patients: A Scoping Review;Clinical Lymphoma Myeloma and Leukemia;2024-01

4. Disparities in Outcomes of Hospitalizations Due to Multiple Myeloma: A Nationwide Comparison;Cureus;2023-10-19

5. STMN1 promotes cell malignancy and bortezomib resistance of multiple myeloma cell lines via PI3K/AKT signaling;Expert Opinion on Drug Safety;2023-08-29